ArticleEJNMMI radiopharmacy and chemistry2024

Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma.

Anthony Waked et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.